Clinical trials: sponsored by Zhejiang Cancer Hospital
Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the…
- Trial name
- NCT05992597
- Testing
- ZR2 RDHAP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Cancer
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
This study was a single-arm, open-label, phase II study of PD-1 monoclonal antibody combined with anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR uncommon mutations.
- Trial name
- NCT04790409
- Testing
- sintilimab and anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Signet Ring Cell Carcinoma
Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics
Gastric signet ring cell carcinoma (GSRCC) possesses unique epidemiology and pathogenesis in the field of cancer, but its incidence is low.
- Trial name
- NCT05985577
- Testing
- Without any intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Double Hit Lymphoma, Triple Hit Lymphoma
XPO-1 in Combination With RCHOP for DH/TH Lymphoma
The purpose of this study was to evaluate the efficacy and safety of Selinexor in combination with RCHOP in first-line treatment of patients with DH or TH lymphoma.
- Trial name
- NCT05974085
- Testing
- Selinexor+RCHOP
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
The goal of this prospective, interventional clinical trial is to evaluation of fruquintinib in combination with sintulimab and TACE for inoperable primary hepatocellular carcinoma for progression-free survival (PFS).
- Trial name
- NCT05971199
- Testing
- Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization（TACE）
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Colorectal Cancer
Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer
To explore the efficacy and safety of Cetuximab in combination with dabrafenib and Tislelizumab in BRAF mutated treatment of advanced colorectal cancer
- Trial name
- NCT05963087
- Testing
- Cetuximab Dabrafenib Tislelizumab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Zhejiang Cancer Hospital
Progression-free Survival
Advanced Pancreatic Cancer
This study is a single-arm, open, single-center clinical study to observe and evaluate the efficacy and safety of sovalteinib in combination with solutumab and tegeo in second-line and post-line treatment of patients with…
- Trial name
- PaC (NCT05958849)
- Testing
- Sovalteinib Solutumab Tegeo
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Colorectal Cancer
Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer
To explore the efficacy and safety of fruquintinib combined with chemotherapy as third-line/third-line+ Treatment in advanced metastatic colorectal cancer
- Trial name
- NCT05928312
- Testing
- Fruquintinib Combined With Chemotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang Cancer Hospital
Postoperative Cognitive Dysfunction, Postoperative Delirium
Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction
The purpose of this study is to determine whether postoperative analgesia pump continuous infusion of dexmedetomidine are effective in the prevention of Postoperative delirium and Postoperative cognitive dysfunction.
- Trial name
- NCT02923128
- Testing
- Dexmedetomidine, Sufentanyl, Saline
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Cancer Hospital
Bile Duct Cancer
Combined Treatment of Treated Bile Duct Cancer
The study will evaluate the efficacy and safety of envelizumab in combination with sovalteinib in the treatment of treated bile duct cancer, and explore treatment options to improve patient survival, while the study will attempt…
- Trial name
- CHOL (NCT05911425)
- Testing
- envolizumab , sovalteinib
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
The investigators design a phase II clinical study to explore the efficacy and safety of Transarterial Chemoembolization (TACE) + Lenvatinib + Icaritin soft capsules in patients with Unresectable, non-metastatic hepatocellular…
- Trial name
- NCT05903456
- Testing
- TACE（transcatheter arterial chemoembolization）, lenvatinib, Icaritin soft capsules
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Extensive Stage Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with Anlotinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive…
- Trial name
- NCT05896059
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
HER2-positive Advanced Breast Cancer
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the…
- Trial name
- HER2-VIP (NCT05856383)
- Testing
- Inetetamab Combined With Pyrotinib and Vinorelbine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Malignant Tumors of Digestive Tract
Multi-omics Study of Tongue Coating in Malignant Tumors of Digestive Tract
This is a prospective, multi-center, observational cohort study and seeks to enroll 20000 patients with one malignant tumor of digestive tract or healthy individual.
- Trial name
- NCT05794841
- Testing
- Tongue coating sample collection and multi-omics analysis
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Renal Cell Carcinoma
A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma
Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials showning better response in unselected patients with metastatic renal cell carcinoma (RCC).
- Trial name
- NCT05705583
- Testing
- Other: Blood and Urine Collection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Thymoma
Single Cell Sequencing Analysis of Thymoma
The purpose of this study is to understand how genetics play a role in thymoma. Intratumoral heterogeneity is among the greatest challenges in precision cancer therapy.
- Trial name
- NCT04162691
- Testing
- Tissue
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Second Line Treatment of Gastric Cancer
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study is a multicenter, open, and randomized clinical phase II exploratory study. The "pick the winner" study design is used to determine and select which chemotherapy drug (irinotecan vs.
- Trial name
- NCT05669807
- Testing
- Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan
- Volunteers
- 184 people
- Sponsor
- Zhejiang Cancer Hospital
Toripalimab, Radiation
A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status
pMMR/MSS and 32 dMMR/MSI-H patientspatients were planned to be enrolled. Patients with dMMR/MSI-H will be randomly assigned to the immunotherapy arm or short-course radiotherapy sequential immunotherapy arm; pMMR/MSS patients…
- Trial name
- NCT05669092
- Testing
- Toripalimab, CRT, SCRT
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Nasopharyngeal Carcinoma
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
Radiotherapy and immunotherapy have achieved good survival benefit in advanced nasopharyngeal carcinoma. A number of clinical studies of immunotherapy combined with radiotherapy for nasopharyngeal carcinoma are also ongoing.
- Trial name
- NCT05652192
- Testing
- SBRT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital